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Abstract
Purpose—In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and 
the CD8+ T-cell infiltrate were associated with a better prognosis. However, the precise role of B 
cells in the antitumor response remains unknown. As peritoneal metastases are often responsible 
for relapse, our aim was to characterize the role of B cells in the antitumor immune response in 
HGSOC metastases.
Experimental Design—Unmatched pre and post-chemotherapy HGSOC metastases were 
studied. B-cell localization was assessed by immunostaining. Their cytokines and chemokines 
were measured by a multiplex assay, and their phenotype was assessed by flow cytometry. Further 
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in vitro and in vivo assays highlighted the role of B cells and plasma cell IgGs in the development 
of cytotoxic responses and dendritic cell activation.
Results—B cells mainly infiltrated lymphoid structures in the stroma of HGSOC metastases. 
There was a strong B-cell memory response directed at a restricted repertoire of antigens and 
production of tumor-specific IgGs by plasma cells. These responses were enhanced by 
chemotherapy. Interestingly, transcript levels of CD20 correlated with markers of immune 
cytolytic responses and immune complexes with tumor-derived IgGs stimulated the expression of 
the costimulatory molecule CD86 on antigen-presenting cells. A positive role for B cells in the 
antitumor response was also supported by B-cell depletion in a syngeneic mouse model of 
peritoneal metastasis.
Conclusions—Our data showed that B cells infiltrating HGSOC omental metastases support the 
development of an antitumor response.
Introduction
The immune system can both limit and promote cancer development. Immune cells infiltrate 
tumors, and recent trials showed how unleashing a tumor-specific immune response with the 
use of tumor vaccines or immune checkpoint blockade can constitute a successful cancer 
therapy (1, 2). The majority of cancer immunology studies have concentrated on the 
protumor or antitumor abilities of T cells or myeloid cells. Less is known about the role of B 
cells in the tumor micro-environment, especially their contribution to the metastatic niche. In 
preclinical models of melanoma, squamous cell carcinoma and carcinogen-induced skin 
cancer, B cells promote tumor progression through the production of immune regulatory 
cytokines and immune complexes (IC; refs. 3–5). On the other hand, in human primary 
tumors, the presence of B cells in association with tertiary lymphoid structures (TLS) in 
non-small cell lung carcinoma (NSCLC) and colorectal, ovarian, and pancreatic cancers has 
been associated with a better prognosis (6–9). In these tumors, the presence of both B cells 
and dendritic cells (DC) correlated with an increase in Th1 signature, which might explain 
the correlation with better survival.
Very few studies have described the immune landscape of human metastases. Lymphoid 
structures were identified in cutaneous metastases of melanoma patients (10) as well as in 
lung metastases of colorectal cancer and renal cell carcinoma (RCC) patients (11). 
Interestingly, a high infiltration of CD8+T cells and DC-LAMP+ DCs correlated with an 
increased overall survival (OS) of patients with colorectal cancer, whereas this correlated 
with decreased OS of patients with RCC (11). B cells have been described in TLS; however, 
their role in the tumor immune landscape remains unclear. In primary ovarian cancer 
biopsies, intratumor infiltration of CD27− atypical memory B cells, together with CD8+ T 
cells, is linked to better prognosis (12). A very recent study also showed that a high infiltrate 
of T cells, B cells, and plasma cells in primary tumors is linked to the presence of TLS in the 
microenvironment and improved survival of patients (13). Whether B cells behave the same 
way in ovarian cancer metastases and how they influence the antitumor response is 
unknown.
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The term ovarian cancer refers to a group of five diseases defined as high-grade serous, low-
grade serous, mucinous, endometrial, and clear cell carcinomas that are known to arise from 
different organs and have different molecular and transcriptomic profiles but all spread into 
the peritoneal cavity (14, 15). High-grade serous ovarian cancer (HGSOC) is the most 
common subtype, representing about 70% of cases and the majority of deaths from ovarian 
cancer (14). Early detection of the disease is one of the biggest challenges, as most patients 
are diagnosed at an advanced stage with metastases disseminated in the peritoneal cavity. 
Platinum-based chemotherapy and surgical de-bulking represent the baseline treatment for 
HGSOC and can prolong survival, although the majority of patients eventually relapse and 
die of peritoneal disease. Therefore, understanding the biological properties of the peritoneal 
metastases and their immune infiltrate is essential to develop new treatment strategies that 
target the tumor deposits responsible for relapse.
In order to elucidate the role of B cells in omental metastasis from HGSOC patients, we 
analyzed 92 omental samples obtained after surgery. B cells were located mainly in 
lymphoid aggregates, which displayed characteristic features of TLS. The majority of B 
cells had a memory phenotype, displayed a restricted clonal repertoire compared with 
peripheral healthy B cells and produced cytokines and chemokines known to recruit and 
activate antitumor immune cells, such as DCs, T cells and NK cells. Using RNAseq analyses 
and in vivo experiments, we also showed that B cells are implicated in immune cytotoxic 
responses.
Furthermore, B cells differentiated to plasma cells and produced immunoglobulins (Ig) 
against tumor targets. Igs can be found bound to antigen-presenting cells (APC) in the tumor 
stroma, coculture of APCs with ICs generated in vitro with tumor IgGs increased the 
expression of the costimulatory molecule CD86, suggesting that Igs might promote an 
antitumor response through potentiation of DC priming. Overall, our data suggest that B 
cells favor the development of an antitumor immune response in omental metastasis of 
HGSOC.
Materials and Methods
Patient samples
Omental tissues were collected from HGSOC patients (FIGO stage III and IV) prior to or 
following platinum-based chemotherapy treatment (Supplementary Table S1). Samples were 
either formalin fixed and paraffin embedded or snap frozen and stored at − 80°C or 
processed as fresh tissues. Blood samples from pre-and post-chemotherapy patients were 
collected in sodium heparin tubes for plasma separation and EDTA tubes for cell analysis. 
Control blood was collected from 12 healthy volunteers. Institutional review board approval 
was granted for the Barts Gynae Tissue Bank to collect and store biological material and 
clinical information. Patients were treated at St Bartholomew's Cancer Centre between 2010 
and 2016 and gave written informed consent. Clinical parameters were collected using tissue 
repository databases and chart review.
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Cell lines
The AOCS1 cell line was kindly given by Professor David Bowtell (Peter MacCallum 
Cancer Centre, Melbourne, Australia) and was established from the ascites of a patient 
diagnosed with HGSOC, Silverberg Grade 3, after second relapse.The G33 cell line was 
established in our laboratory from an omental HGSOC tumor collected during interval 
debulking surgery in 2011 (16). The cell lines have been authenticated. Cells were cultured 
in DMEM/F12 (Gibco), 10% FCS, 2 mmol/L L-glutamine, 1% penicillin and streptomycin 
in a 5% CO2 humidified incubator at 37° C. Regular checks for mycoplasma contamination 
were performed.
Tissue processing and flow cytometry
The stroma vascular fraction (SVF) was isolated from fresh omentum by mechanical 
dissection of the tissue with a scalpel and collagenase D digestion for 30 minutes at 37°C 
(Roche). Digested samples were filtered through 70-μm strainers, and the SVF were used for 
FACS analyses. Fresh peripheral blood mono-nuclear cells (PBMC) were isolated from 
blood samples by centrifugation with Ficoll-Paque Plus (GE Healthcare).
Cell suspensions were stained with different antibody panels for 30 minutes on ice in PBS, 
2.5% bovine serum albumin, and 2 mmol/L EDTA. Cells were then washed twice and 
analyzed directly by FACS or fixed in PBS 2% formalin for 10 minutes at 4°C before being 
analyzed. Antibodies and viability dyes are shown in Supplementary Table S2. Appropriate 
fluorescence minus one (FMO) controls were used in these experiments. Analysis was 
performed using an LSR Fortessa cell analyzer (BD Biosciences).
Immunostaining of FFPE sections
Paraffin-embedded sections from HGSOC omental metastases were stained for CD20, CD4, 
CD8, IgG, IgM, CD68, Ki67, FDC, Myeloperoxidase (MPO; Dako), MECA79 (Biolegend), 
and DC-LAMP (Sigma). Sections were deparaffinized in xylene for 10 minutes and re-
hydrated by successive immersion in 100%, 90%, 70%, 50% EtOH and H2O. Heat-induced 
antigen retrieval was performed with Citrate Buffer (Vector Labs) for 20 minutes in a 
pressure cooker.
Immunohistochemistry—Slides were blocked in PBS 2.5% BSA and 2.5% goat serum 
for 40 minutes at room temperature (RT) and biotin/streptavidin blocking buffer (Vector 
Labs) according to the manufacturer's recommendations. Primary and secondary antibodies 
were applied for 1 hour at RT. Enzymatic activity was revealed with the Vectastain ABC 
Elite kit (Standard; Vector Labs) and Sigma FAST 3,3-diaminobenzidine tablets (Sigma). 
Sections were counterstained with hematoxylin and mounted with DPX mounting medium 
(Sigma).
For dual-stain immunohistochemistry, antibodies were incubated sequentially and revealed 
with the Vectastain system previously described. FAST 3,3-diaminobenzidine tablets were 
used to generate the brown color, and the Immpact VIP peroxidase substrate kit (SK-4605 
Vector labs) generated the purple color. Sections were mounted with Dako Faramount 
aqueous mounting medium.
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Brightfield pictures we taken with an Axiophot microscope (Zeiss). CD20, DC-LAMP, and 
MPO single-stained slides were scanned using a Pannoramic Scanner (3D HISTECH) and 
analyzed with the “Tissue Studio” software 4.0 (Definiens).
To assess numbers of MPO+ neutrophils and DC-LAMP+ DCs in lymphoid structures, 2 to 5 
TLS per tumor were analyzed to obtain a mean number of positive cells per TLS for each 
metastasis. Intravessel cells were excluded from the counts.
Immuno fluorescence—Slides were incubated for 20 minutes in NH4 Cl (50 mmol/L) to 
reduce autofluorescence and blocked in PBS 2.5% BSA, 2.5% goat serum for 40 minutes at 
RT. IgG staining was performed prior to any other additional staining. Subsequently, primary 
antibodies were applied overnight at 4° C. The next day, fluorescently labeled secondary 
antibodies (Invitrogen) were incubated for 1 hour at RT, and sections were mounted with 
Prolong gold antifade reagent containing Dapi (Thermo Fisher Scientific).
The specificity of the stainings was determined using appropriate isotype controls. 
Fluorescent pictures were taken with an LSM510 confocal microscope (Zeiss).
In vitro DC differentiation and activation
PBMCs were isolated from the blood of 6 healthy volunteers by centrifugation with Ficoll-
Paque Plus (GE Healthcare). CD14+ monocytes were purified using anti-human CD14 beads 
(Miltenyi) and cultured in RPMI 10% FCS, 20 ng/mL recombinant human GM-CSF and 
recombinant human IL4 (Biolegend). After 6 days, monocyte-derived DCs were re-
stimulated with 10 μg/mLof IgGs (purified from protein extracts of two HGSOC omental 
tumors or healthy plasma IgGs and pooled) for 24 hours, pre-incubated or not with 30 mg of 
combined protein extracts from HGSOC cell lines G33 and AOCS1. Expression of the 
costimulation marker CD86 on DCs was assessed by flow cytometry.
Statistical analysis
Data are expressed as the mean of values per sample ± SEM. Statistical significance for flow 
cytometry, immunohistochemistry, and Mesoscale analyses was assessed using the Student t 
test or a nonparametric test (Mann-Whitney) when appropriate. Spear-man or Pearson tests 
were used for correlation analyses. Data normal distribution was assessed using the D 
Agostino & Pearson omnibus normality test. Data were considered statistically significant 
from P < 0.05.
For the mouse experiment, luminescence intensity values were log10 transformed before 
applying a one-way ANOVA test to account for heteroscedasticity of results.
For BCR sequencing data analyses, we used the species richness, the Gini-Simpson index 
and the Shannon entropy as diversity indexes.
Finally, for the RNAseq data analysis, significantly differentially expressed genes were 
identified using a double threshold of false discovery rate (FDR) < 0.05 and an absolute fold 
change > 2.
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Results
Presence of B cells in TLS in HGSOC omentum is associated with the generation of 
memory B-cell responses
To assess the presence and localization of B cells in HGSOC omental metastases, paraffin 
sections from unmatched biopsies taken pre- (n = 10) and post- (n = 31) neoadjuvant 
chemotherapy (NACT) were stained for the B-cell marker CD20 (Supplementary Table S3). 
CD20+ B cells were localized mainly in lymphoid aggregates in the stroma, next to tumor 
islets (Fig. 1A and B). There was no significant difference in the number of B cells in pre 
and post NACT biopsies, suggesting that chemotherapy neither impairs nor increases B-cell 
infiltration in omental metastases (Fig. 1C). Because similar lymphoid structures were 
described in other solid cancers as TLS (7, 10, 17), we further characterized the B-cell-rich 
follicles using immunohistochemistry and immunofluorescence. We often observed a core of 
CD20+ B cells surrounded by a T-cell-rich area of mainly CD4+ T cells, whereas CD8+ T 
cells were located at the periphery of the lymphoid aggregates (Fig. 1D). In addition, high 
endothelial venules (HEV; blood vessels specialized in the recruitment of immune cells 
within lymphoid organs) were present, as indicated by MECA79 staining (Fig. 1E). By 
double-color immunohistochemistry we also identified areas rich in follicular DCs and 
Ki67+ highly proliferative germinal center B cells surrounded by CD45RO+ memory cells 
(Fig. 1F). Taken together, these features indicate the presence of TLS in HGSOC omental 
metastases.
TLS are implicated in the differentiation of antigen-specific B cells and development of 
memory responses (8). To assess the B-cell composition of HGSOC omental metastases, 
flow cytometry analysis of cells extracted from 25 fresh HGSOC omenta was carried out. 
Results showed that a majority of omental B cells display a “classical” (CD27+IgM+ and 
CD27+IgM−) or “atypical” (CD27−IgM−) memory phenotype (Fig. 2A and B). Interestingly, 
we observed a significant increase in the proportion of class-switched memory B cells 
(CD27+IgM−) in metastases from NACT-treated patients compared with pre-chemotherapy 
patients (Supplementary Fig. S1A). This was accompanied by a decrease in CD20+-naïve B 
cells after chemotherapy treatment, although data did not reach statistical significance. The 
extent of residual disease did not seem to impact significantly on the proportion of class-
switched memory B cells after chemotherapy (Supplementary Fig. S1A).
The percentage of naïve B cells was on average 28.2% of CD20+ cells in omental metastasis 
(Fig. 2B), lower than that in patient blood (mean 47.8%; Supplementary Fig. S1B). This 
difference suggested that there was an ongoing B-cell response in HGSOC patients that 
drove B-cell differentiation and might have taken place in TLS at sites of metastasis.
Further analyses of B-cell subpopulations demonstrated that a higher proportion of class-
switched memory B cells (CD20+CD27+IgM∼ and CD20+CD27−IgM−) expressed the 
costimulatory molecule CD86 when compared with IgM+ memory (CD27+IgM+) and naive 
(CD27−IgM+) B cells (Fig. 2C). No difference in CD86 expression was observed between 
pre and post chemotherapy patients (Supplementary Fig. S1C). Nonetheless, all memory B-
cell subpopulations also upregulated the inhibitory receptor PD1, albeit to a lesser extent 
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(Fig. 2D; Supplementary Fig. S1D). Coexpression of CD86 and PD1 on B cells was 
generally low (Supplementary Fig. S1E and S1F).
To investigate whether omental B cells were mounting an antigen-specific response, we then 
analyzed their clonal repertoire by B-cell receptor (BCR) sequencing. We extracted RNA 
from purified omental HGSOC B cells and peripheral B cells from healthy individuals and 
sequenced the IgH portion of the B-cell receptor. We report here three common 
mathematical indices of diversity calculated from the IgH repertoire data: the species 
richness (defined as the number of unique IgH clono-types in the sample), the Shannon 
entropy (which equally weights a species richness term and a term that increases with 
increasing clonal dominance), and the Gini–Simpson index (which weights the dominance 
term more heavily than the species richness term). For all diversity indices, HGSOC B cells 
showed decreased diversity relative to healthy donor B cells (Fig. 2E). This observation was 
in accordance with an increase in the rate of somatic hypermutations in Igs from HGSOC 
omentum compared with healthy B cells (Fig. 2F).
So far, our results suggest that B cells in HGSOC omentum are activated, differentiate to a 
memory B-cell phenotype and undergo clonal selection.
B cells correlate with the infiltration of DC-LAMP+ DCs and an immune cytolytic signature 
in HGSOC omentum
B cells secrete proinflammatory and/or regulatory cytokines and chemokines that can 
influence the development of specific immune responses, as previously found in different 
cancer models (18, 19). To determine how the secretome of HGSOC B cells could influence 
the antitumor immune response, B cells from omental metastases were purified and 
stimulated for 48 hours with a low dose of PMA and Ionomycin (PMA/Iono). The secretion 
of cytokines and chemokines was analyzed by electroche-moluminescence multiplex assay 
and healthy peripheral B cells were used as a control.
The heatmap shown in Fig. 3A highlights the relationship existing between 24 cytokines and 
chemokines produced by HGSOC omental B cells and suggests an immune-stimulatory role 
for B cells. In addition to secretion of cytokines and chemokines (GM-CSF, IFNγ, IL12p40, 
CXCL10, and IL7) that can broadly recruit and support macrophages, DCs, T cells, and NK 
cells, tumor omental B cells produced significant amounts of inflammatory cytokines, such 
as CXCL8, CCL2 and IL6, even in the absence of PMA/ionomycin stimulation (Fig. 3B-D). 
Median concentrations were 19,694 pg/mL for CXCL8, 885.5 pg/mL for CCL2, and 51.4 
pg/mL for IL6, as opposed to 2,178 pg/mL, 2.19 pg/mL and 2.027 pg/mL, respectively, in 
HGSOC and healthy peripheral B cells.
When we analyzed the expression of the CXCL8 receptors CXCR1 and CXCR2 on immune 
cells from HGSOC omentum we observed that, in accordance with previously published 
evidence (20), granulocytes expressed the highest levels of both receptors, whereas DCs 
expressed significant but lower levels of CXCR1 and CXCR2 (Fig. 3E). B and T cells had 
very low expression of these two chemokine receptors. These results suggest that through 
the production of CXCL8, B cells are implicated in the recruitment of both DCs and 
granulocytes in omental metastases and more specifically in TLS. Given that the majority of 
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granulocytes in HGSOC omentum are neutrophils (data not shown), we stained HGSOC 
omental tumors for the neutrophil marker MPO (myeloperoxidase) and DC marker DC-
LAMP and assessed the localization of DCs and neutrophils in the tumor microenvironment 
(Fig. 3F). Three times less neutrophils than DCs were observed in TLS. We next studied 
whether there was a correlation between the number of CD20+ B cells and DC-LAMP+ DCs 
in HGSOC omentum. Immunohistochemistry staining and digital analysis of 16 FFPE 
sections from HGSOC omental metastases showed a significant correlation between the 
density of B cells and DCs in the stroma area of omental tumors (Fig. 3G).
In lung cancer, thepresence of B-cell–rich TLS and DCs has been linked to good prognosis 
and the development of a Th1 signature (21). Because activated DCs can stimulate CD8+ T 
cells and promote a cytotoxic response and B cells and DC densities were correlated in 
HGSOC metastases (Fig. 3G), we assessed whether the B-cell infiltrate correlated also with 
a cytotoxic response. To this end, we analyzed RNA from HGSOC omental metastasis by 
RNAseq and examined transcriptional changes between uninvolved stage 1/2 HGSOC 
omentum (n = 6), stage 3/4 untreated (n = 4), chemotherapy-treated diseased omentum (bad 
responders; n = 7), and chemotherapy-treated omentum with low residual disease (good 
responders; n = 5). When comparing gene expression levels between these groups, 44 genes, 
characteristic of a B-cell signature, were significantly increased in omental metastases (stage 
3/4 pre and post chemo and stage 3/4 good responders as opposed to stage 1/2; Fig. 4A–D). 
We next analyzed the correlation between the transcript levels of CD20 in stage 3/4 HGSOC 
omentum and the immune cytotoxic markers granzyme A (GZMA) and perforin (PRF1; ref. 
22). Not only did we observe a strong correlation between the levels of CD20 and GZMA or 
PRF1 transcripts (Pearson r = 0.73 and 0.61, respectively; data not shown) but CD20 
expression also strongly correlated with the geometric mean of the combined parameters 
(Fig. 4E). This suggested that B cells contribute favorably to the development of an 
antitumor immune response.
The above associations were supported by an experiment using a syngeneic mouse model of 
ovarian cancer, in which the mouse cell line ID8 is injected intraperitoneally and tumor 
growth is monitored over the course of 8 weeks. We depleted CD20+ B cells in tumor-
bearing mice with an anti-CD20 antibody and found that B-cell depletion was associated 
with an increased tumor progression (Fig. 4F, left) and a reduced T-cell cytotoxic activity, as 
indicated by decreased expression of the degranulation marker CD107 from asciticCD8+T 
cells (Fig. 4F, bottom right).
Collectively, our results suggest that through the production of cytokines and chemokines 
that help recruit and support antigen-presenting cells, B cells could enhance the development 
of an immune cytotoxic response toward tumor cells.
Immunoglobulin production by intratumor plasma cells
Active germinal center reactions in TLS are normally associated with differentiation of 
plasma cells that secrete antigen-specific immunoglobulins. Indeed, HGSOC omenta 
appeared to contain a plasma cell infiltrate, as demonstrated by the presence of 
CD38++CD19+/− CD20−CD27+ cells (Fig. 5A and B). Furthermore, we observed high levels 
of IgG deposits in HGSOC omenta, mainly located in stromal areas but also bound to tumor 
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cells and macrophages (Fig. 5C). IgM immunoglobulins were also detected but to a lesser 
extent (Supplementary Fig. S2A). Mass spectrometry analysis of proteins extracted from 
three HGSOC omental metastases confirmed that IgG immunoglobulins represent the largest 
subclass, with IgM and IgA representing less than 15% of total antibodies. IgE 
immunoglobulins were not detected under these conditions (Supplementary Fig. 
S2B).Wenext examined the amount of IgG1, IgG2, IgG3, and IgG4 subclasses in HGSOC 
omenta from different disease stages (1/2 vs. 3/4) with high or low residual disease 
(Supplementary Table S4). Figure 5D shows an increase in the presence of IgG1, IgG2, and 
IgG3 in stage 3/4 omenta compared with stages 1/2 (Fig. 5D; Supplementary Fig. S2C). 
Furthermore, IgG3 was significantly increased in post-chemotherapy diseased samples 
compared with pretreatment samples. On the other hand, IgG4 levels seemed to increase in 
stage 3/4 prechemotherapy tumors compared with stage 1/2 uninvolved omenta but had a 
tendency to decrease post-chemotherapy. Importantly, HGSOC patient plasma levels of IgG 
sub-classes were not different from healthy controls (Supplementary Table S5 and 
Supplementary Fig. S2D and S2E), suggesting that a tumor-specific antibody response 
preferentially takes place at the tumor site in TLS.
Next, to assess the ability of omental IgGs to recognize membrane bound and/or 
intracellular tumor antigens, we isolated immunoglobulins from three HGSOC omental 
tumors (G146, G168, and G175) and tested their reactivity toward intact or permeabilized 
tumor cells (AOCS1 and G33 HGSOC cell lines) by flow cytometry and 
immunofluorescence, respectively (Supplementary Fig. S3A–S3C). IgGs from all three 
omenta mainly targeted intracellular antigens, either cytoplasmic or nuclear (Supplementary 
Fig. S3A and B); nonetheless, IgGs extracted from the G175 and G146 omental tumors were 
able to recognize antigens expressed at the surface of a subpopulation of the HGSOC tumor 
cell line AOCS1 (Supplementary Fig. S3C).
To determine the nature of these antigens, we carried out immunoprecipitation experiments 
using purified tumor immunoglobulins as bait and assessed proteins pulled down by mass 
spectrometry. Total tumor lysate and control bead extracts were used as controls. Proteins 
found enriched in the IP fraction (but not in the control bead extracts) compared with the 
total tumor lysate were considered potential targets of intratumor IgGs (Table 1).This assay 
identified a number of targets of omental IgGs,some of which were validated by IHC. The 
proteins GNA13 (Guanine nucleotide binding protein (G) 13),DPYSL3 (Dihydropyrimidase 
like 3 or CRMP4), and HSPB1 (heat shock protein B1) were detected in paraffin sections of 
HGSOC omenta (Supplementary Fig. S3D).We concluded from these experiments that the 
majority of immunoglobulins were binding antigens released inthe tumor microenvironment 
after tumor cell death. Nevertheless, the extensive deposition of immunoglobulins bound to 
antigens, called immune complexes (ICs), could still be playing a role in the antitumor 
response, because ICs can activate APCs via ligation of Fc gamma receptors (FcγR; refs. 
23, 24). Therefore, we assessed whether purified intratumor IgGs were playing a role in the 
activation of APCs in vitro. In these experiments, we treated monocyte-derived DCs with 
tumor-derived IgGs, preincubated or not with protein extracts from HGSOC cell lines in 
order to generate ICs. IgGs from healthy blood, alone or incubated with tumor antigens, 
were used as controls (Fig. 5E). Treatment of monocyte-derived DCs with in vitro–generated 
tumor ICs significantly increased the expression of the costimulatory molecule CD86 
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compared with healthy IgGs in combination with tumor antigens. This suggested that IgGs, 
likely produced by intratumor plasma cells, recognize tumor antigens and form ICs that 
contribute to the activation of APCs in the tumor microenvironment.
Discussion
In this study, we set out to elucidate the role played by B cells in HGSOC metastases by 
analyzing human biopsies. From previous studies, it was known that high levels of CD8+ T-
cell infiltration of primary human ovarian tumors were associated with an increased survival 
(25) and that patients displaying high tumor-infiltrating T cells, CD20+ B cells and plasma 
cells exhibited an additional survival advantage (12, 13). This was reinforced by analyses of 
the TCGA ovarian cancer dataset, showing a positive correlation between a B-cell gene 
expression signature and progression-free survival in immunoreactive ovarian tumors (26). 
However, data were limited to primary tumors and not peritoneal metastases, which are 
generally responsible for the high rate of recurrence in HGSOC. In our work on omental 
metastases, we found that B cells in HGSOC omentum were mainly located in lymphoid 
structures and a high proportion exhibited a memory pheno-type. These results were in 
accordance with those of the above-mentioned study demonstrating memory B cells in 
primary ovarian tumors, which correlated with a good prognosis (12). Furthermore, a similar 
role for B cells was also described in NSCLC (8). We do not have sufficient samples to 
assess correlations with survival; nonetheless, our results indicate that B cells take part and 
positively influence the development of an antitumor response. This is in agreement with a 
preclinical study showing that depletion of B cells using anti-CD20 antibodies in the B16 
melanoma model impairs CD8+ T-cell antitumor immunity and promotes cancer 
development (27). Interestingly, we observed that depletion of B cells in the ID8 ovarian 
mouse model decreased the expression of the degranulation marker, CD107, on CD8+ T 
cells. This was accompanied by increased tumor growth and suggested that depletion of B 
cells impairs the T-cell–dependent antitumor cytotoxic response. In accordance with these 
results, RNAseq analyses of human omental metastases showed CD20 transcript levels 
significantly correlated with levels of cytolytic markers (22), hence linking B cells to 
immune cytotoxic responses in patients' metastases.
It is interesting to note that chemotherapy neither affected the enrichment in B-cell signature 
nor the density of CD20+ B cells; however, class-switched memory B cells were enhanced 
after NACT. Although we cannot rule out a direct effect of chemotherapy on survival and 
migration of B cells, it is possible to speculate that following chemotherapy the release of 
tumor antigens in the microenvironment provides a boost for the activation and 
differentiation of B cells. Nonetheless, these results are in accordance with studies 
describing the immune-stimulatory properties of chemotherapeutic agents such as 
anthracyclins, which causes immunogenic cell death of tumor cells (28) and platinum-based 
chemotherapy, shown to promote T-cell activation and down-regulation of immune-
modulatory molecules on DCs (29). Our results indicate that chemotherapy has a positive 
influence also on B-cell responses.
Next, we observed that omental B cells produced a network of cytokines and chemokines, 
including IFNγ, IL12, GM-CSF and CXCL10, compatible with the development of 
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antitumor responses, most likely occurring within TLS. HGSOC omental B cells also 
secreted high amounts of CXCL8, a chemoattractant for neutrophils and DCs. Indeed, 
CXCR1 and CXCR2 receptors for CXCL8 were detected on omental DCs and neutrophils. 
Although neutrophils expressed higher levels of both receptors, more DCs than neutrophils 
infiltrated the lymphoid structures found in omental metastases. A more complex 
chemotactic network comprising CCL2, CXCL8, GM-CSF but also additional unidentified 
factors might explain this observation. Interestingly and in accordance with a study 
conducted in NSCLC (8), stromal densities of CD20+ B cells and DC-LAMP+ DCs 
correlated in omental tumors. In vitro studies recently demonstrated that activated B cells 
could induce the maturation of monocyte-derived DCs, rendering them competent for T-cell 
activation (30). Whether omental B cells directly support maturation of DCs in a similar 
fashion remains to be determined. None-theless, the spatial distribution of B cells and DCs 
within the TLS and B-cell cytokine and chemokine production suggest that B cells promote 
not only DC recruitment but also their differentiation. Are B cells also involved in increasing 
DC antigen-presenting ability? In this respect, we observed a high deposition of IgGs in the 
tumor stroma, some of which were bound to APCs. Several factors might contribute to this 
stromal localization: (i) the extracellular matrix could impair the diffusion of IgGs, 
preventing them from reaching tumor cells; (ii) ongoing cell death due to necrosis, 
chemotherapy, and/or immunity, which favors the release of antigens in the 
microenvironment, hence sequestering antigen-specific IgGs in the stroma; (iii) IgGs 
targeting intracellular antigens that cannot be easily accessible. We confirmed that 
intratumor IgGs preferentially target intracellular antigens, although some cytoplasmic 
proteins can be abnormally exposed at the surface of cancer cells (31). Nonetheless, previous 
studies provided evidence that Igs targeting intracellular antigens possess anticancer 
properties either by reaching their targets, possibly through internalization by cancer cells 
(32, 33) or by activating APCs through FcR, which in turn stimulate T-cell responses (34). In 
support of this latest hypothesis, we found that immunoglo-bulins from HGSOC metastases 
can form ICs with tumor antigens and promote expression of the coactivatory molecule 
CD86 on in vitro generated DCs. These results indicate that ICs present in the tumor stroma 
could increase DC antigen-presenting capabilities.
Contrary to studies showing an increase in IgG4 antibodies in cutaneous metastases of 
melanoma patients (35), the pre-dominance of IgG1, IgG2, and IgG3 over IgG4 antibodies 
in HGSOC metastases, especially following chemotherapy treatment, highlighted their 
potential to trigger APC activation, through binding to activatory FcgRs (36, 37). It is 
interesting to note that in post-chemotherapy omentum displaying low residual disease, the 
decrease in tumor IgGs, mirrored by the decrease in the B-cell infiltrate in the tumor, is 
likely to be linked to a partial resolution of the antitumor immune response with a decreased 
number of TLS.
In conclusion, our study demonstrated for the first time that in human metastases of 
HGSOC, B cells develop memory responses in the tumor microenvironment, likely via their 
association with TLS. In this context, their activated phenotype, secretion of 
proimmunogenic cytokine/chemokines and production of IgGs targeting tumor antigens is 
associated with an enhanced recruitment and priming of DCs and promotion of immune 
cytotoxic responses. Our study provides supporting evidence that ICs of antitumor IgGs 
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bound to tumor antigens could be beneficial in the clinic and potentiate antitumor responses. 
This approach has already been tested in a preclinical study (23) and should be further 
explored in a cancer setting. Because we show that chemotherapy further enhances the 
antitumor B-cell response, these new approaches would be compatible and aided by current 
treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
Little is known about how B cells interact with other players of the tumor immune 
landscape in HGSOC, especially in the context of a metastatic disease. The present study 
provides evidence for a positive role of B cells in the development of an antitumor 
immune response at metastatic sites, an effect that can be enhanced by chemotherapy 
treatment. A better understanding of these processes is essential for developing new 
anticancer immunotherapy strategies. We show that it would be beneficial to take 
advantage of B cells and their immunoglobulins to boost the antitumor immune 
responseinpatients with advanced-stage HGSOC, in particular to increase DC recruitment 
to tertiary lymphoid structures and their anti-gen-presenting ability. This could be 
exploited in dendritic cell–based vaccination protocols or as adjuvant to different 
anticancer treatments.
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Figure 1. 
B cells in HGSOC are found in tertiary lymphoid structures. A, Immunohistochemistry 
pictures showing two representative sections from paraffin-embedded HGSOC omentum 
stained for CD20. Scale bar, 200 μm. B and C, Log2 density of CD20+B cells in HGSOC 
omental metastases. B, Comparison of CD20+ B cell densities in tumor versus stromal areas 
(n = 33; ***, P < 0.001; Mann-Whitney test). C, Comparison of CD20+ B-cell densities in 
the stroma of unmatched HGSOC metastases obtained before (n = 10) and after 
chemotherapy treatment (n = 31). D-F, Characterization of the B-cell-rich lymphoid 
structures by single-color immunohistochemistry, immunofluorescence, and double-color 
immunohistochemistry. D, Identification of CD20+ B cells, CD4+, and CD8+ T cells within 
TLS. Scale bars, 50 μm. E, Presence of MECA79+ high endothelial venules in TLS. Scale 
bars, 20 mm. F, Germinal centers of TLS contain follicular DCs (FDC) and Ki67+ high 
proliferating cells surrounded by CD45RO+ memory cells. Scale bars, 50 μm.
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Figure 2. 
Memory B-cell response in HGSOC metastases. A and B, Flow cytometry analysis of the B 
subpopulations in HGSOC omentum (n = 25) showing differential expression of CD27 and 
IgM within the CD20+ cells. Representative plots (A) and percentages (B) of the different B-
cell subpopulations: IgM+ memory (CD27+IgM+), class-switched memory or IgM− memory 
(CD27+IgM−), CD27− atypical memory (CD27−IgM−) and naive (CD27−IgM+) B cells. An 
example of IgD expression in the different subpopulations is shown. C and D, Proportion of 
CD86+PD1− (C) and PD1+CD86− (D) cells among the B-cell subsets described above (n = 
11; *, P < 0.05; **, P < 0.01; ***, P < 0.001; Mann-Whitney test and Student t test). E and 
F, BCR sequencing of B cells from HGSOC omentum (O; n = 7) and blood (B; n = 1) 
compared with healthy peripheral B cells (ctrl; n = 7). E, Diversity analysis of the B-cell 
repertoire. Error bars, 95% confidence interval (38). F, Analysis of hypersomatic mutations. 
IgH mutation rates for each sample (top). Tumor and nontumor samples were binned and 
IgHV mutation rates were compared (bottom).
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Figure 3. 
Role of B cells in the recruitment of DCs in HGSOC metastases. A-D, Cytokine/chemokine 
secretion of HGSOC omental B cells (see Supplementary Methods). A, Correlation heatmap 
showing how the levels of the 24 cytokines and chemokines measured in the supernatant of 
HGSOC B cells (n = 4–10) vary with each other. Columns and rows represent individual 
cytokines and chemokines colored to indicate Pearson's correlation coefficient (r). B-D, 
Log2 concentrations of CXCL8, CCL2, and IL6 in the supernatant of unstimulated healthy 
peripheral B cells (n = 2); PMA/ionomycin- (PMA/Iono) treated healthy peripheral B cells 
(n = 5–7); unstimulated and PMA/ionomycin-treated HGSOC omental B cells (n = 9–10; *, 
P < 0.05; ***, P < 0.001, Student t test). E, Flow cytometry analysis of CXCR1 (n = 4) and 
CXCR2 (n = 3) expression on CD19+ B cells; CD3+ T cells, CD11b++CD14+CD11c− 
macrophages; CD11b++CD14−CD11c− granulocytes and CD11b++ CD14−CD11c+ DCs 
from HGSOC omentum. F, Representative immunostainings and quantification of DC-
LAMP+ DCs and MPO+ neutrophils in CD20+-rich lymphoid structures in HGSOC omental 
metastases (n = 7). Arrows indicate MPO+ cells. Scale bar, 100 μm; ***, P < 0.001, Student 
t test. G, Correlation analysis between the log2 densities of DC-LAMP+ DCs and CD20+ B 
cells in a cohort of 16 HGSOC patients (2 pre-chemotherapy and 14 post-chemotherapy; P < 
0.05; Pearson correlation test).
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Figure 4. 
B-cell signature is enriched in diseased omentum and linked to cytotoxic response. A-D, 
Heatmap and boxplots showing an increase in expression of B-cell signature genes in 
stage3/4 pre- (n = 4) and post-chemotherapy [post-chemotherapy diseased (post dis),n = 7; 
post-chemotherapy good responders (post good),n = 5)] vs. stage 1/2 (n = 6) non-involved 
HGSOC omentum. *, P < 0.05; **, P < 0.01; Student t test. E, Positive correlation between 
the geometrical mean of levels of expression of granzymeA (GZMA) and perforin (PRF1) 
versus CD20 (MS4A1) in HGSOC stage 3/4 omentum. F, CD20 depletion increased tumor 
progression in the ID8 mouse model. Left, tumor progression in anti-CD20- (n = 5) and IgG 
control- (n = 4) treated mice assessed by luciferase activity monitoring (P = 0.03; Two-way 
ANOVA on log10 luminescence values). Top right, Bcells (CD45+ CD19+) and plasma cells 
(CD45+ CD138+) are depleted in the ascitic fluid of αCD20-treated ID8 mice vs. IgG 
controls. Bottom right, CD107 expression by ascitic CD8+ T cells in αCD20 and IgG 
control-treated ID8 mice (**, P < 0.001; Student t test).
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Figure 5. 
Plasma cells are present in HGSOC omenta and IgGs deposited mainly in stromal areas but 
also on tumor cells and macrophages. A and B, Presence of 
CD38+ +CD19+/−CD20_CD27+plasma cells in HGSOC omentum (n =14; 11). C, Paraffin 
sections of omental metastases were fluorescently stained for CD20, CD68, or Cytokeratin 7 
(CK7) (red) in combination with IgG (green). Arrows indicate colocalization of the CD68 
and CK7 markers with IgG. Scale bar, 20 μm. D, Protein extracts isolated from frozen stage 
3/4 pre-chemotherapy, post-chemotherapy diseased, post-chemotherapy with no/low residual 
disease and stage 1/2 noninvolved omentum were tested for the presence of human IgG1, 
IgG2, IgG3, and IgG4 by ELISA; * P < 0.05, Mann–Whitney. E, Tumor-derived IgGs ICs 
increase the expression of CD86 on DCs in vitro. IgGs were isolated from two tumor lysates 
using Agarose beads coupled to protein A/G and pooled. Monocyte-derived DCs (n =14; 7) 
from healthy volunteers were then treated with tumor IgGs alone or tumor IgGs 
preincubated with protein extracts from HGSOC tumor cells. IgGs from healthy plasma 
were used as a control. CD86 expression on DCs was assessed after 24-hour treatment.
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